Apolipoprotein B Improves Risk Assessment Beyond LDL-C and Non-HDL-C in the Framingham Heart Study

Using data from the Framingham Heart Study, this analysis tested whether apolipoprotein B (ApoB) adds significant information for predicting coronary heart disease (CHD) events beyond what is captured by standard measures: LDL-C and non-HDL-C.

ApoB significantly improved risk prediction beyond both LDL-C (likelihood ratio test p < 0.0001) and non-HDL-C, with a hazard ratio of 1.26 per standard deviation increment of ApoB residuals after adjusting for LDL-C, and 1.20 per SD beyond non-HDL-C. The C-statistic improvement was modest (0.72 to 0.73) — consistent with the recognized limitation that C-statistics are insensitive to risk reclassification — but the Relative Integrated Discrimination Improvement (rIDI) was 11% over LDL-C and 8% over non-HDL-C, indicating meaningful clinical reclassification.

The Framingham findings confirm what Mendelian randomization studies have established: cardiovascular risk correlates with the number of atherogenic ApoB-containing particles, not simply with the cholesterol mass they carry. In patients where LDL-C and ApoB are discordant — particularly those with metabolic syndrome, hypertriglyceridemia, or insulin resistance — ApoB measurement provides risk information that would otherwise be missed.

For clinical practice, this study supports direct ApoB measurement in patients at intermediate risk or those with features that commonly create LDL-C/ApoB discordance.

We rate the evidence strong. A well-designed Framingham cohort analysis establishing ApoB’s independent prognostic value beyond LDL-C and non-HDL-C — supporting the case for routine ApoB measurement in risk stratification.